Loading...
Market
Pharma company with most Zantac lawsuits by end of 2025?
3
Resolution / Starting Odds
GSK • 25%
Sanofi • 25%
Pfizer • 25%
Other • 25%
Court records and official lawsuit counts
Story
GSK Settles 93% of Zantac Cancer Lawsuits for $2.2 Billion
Oct 9, 2024, 06:59 PM
GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle approximately 80,000 U.S. state court lawsuits alleging that its discontinued heartburn medication Zantac, known generically as ranitidine, caused cancer. The settlement covers 93% of the pending product liability cases and involves agreements with ten plaintiff firms, expected to be finalized by the first half of 2025. GSK will recognize a £1.8 billion ($2.3 billion) charge in its third-quarter 2024 results due to the settlement. The U.S. Food and Drug Administration had previously asked manufacturers to remove Zantac from the market over concerns that an ingredient could degrade into a carcinogen. Following the announcement, GSK shares jumped as much as 6.5%.
View original story
Similar markets
Less than 3 • 25%
3 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%
Less than 90% • 25%
90% to 95% • 25%
95% to 99% • 25%
100% • 25%
Less than $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
$3 billion to $3.5 billion • 25%
More than $3.5 billion • 25%
Stock price increases • 25%
Stock price decreases • 25%
Stock price remains stable • 25%
Insufficient data • 25%
Decrease by more than 10% • 25%
Decrease by 5% to 10% • 25%
Decrease by less than 5% • 25%
No significant change • 25%
California • 25%
Texas • 25%
New York • 25%
Other • 25%